
1. Technology overview
Moonlight AI is a Swiss diagnostics software company (legal entity Moonlight Ai GmbH, Courroux, Switzerland). It addresses the cost and delay of genomic testing in blood and cancer diagnostics by reading molecular information that is already encoded in cell morphology.
The platform applies computer vision to whole slide images of routine blood and cytology smears and is trained on paired imaging and genomic results. It detects genomic biomarkers and disease signatures to triage and complement conventional molecular testing, and works with a laboratory's existing imaging hardware. Initial focus areas are myelodysplastic syndrome, non-small cell lung cancer and chronic lymphocytic leukemia, and the target buyers are diagnostic laboratories.
2. Highlighted features & specifications
- Morphology-to-genomics AI: Computer vision links cell appearance to genomic biomarkers.
- Smear imaging input: Works on routine blood and cytology smear images.
- Whole slide image analysis: Processes digitized slides from the laboratory.
- Triage of molecular testing: Complements conventional tests by flagging cases of interest.
- Existing hardware compatibility: Integrates with the imaging equipment a lab already runs.
3. Potential application
A hospital hematology laboratory in Vietnam could pre-screen blood smears to prioritize patients for molecular panels. A private diagnostic chain could add morphology-based triage to its cytology workflow to lower per-case testing cost.
4. Benefits
Laboratories can screen for genomic signatures from slides they already produce. The software integrates with existing imaging hardware, so no new instruments are needed. It is positioned to triage cases for molecular testing and reduce reliance on routine sequencing.
5. Market trends & opportunities
Digital pathology and AI-assisted hematology are growing as laboratories look to cut sequencing costs and turnaround time. In Vietnam and Southeast Asia, large hospital laboratories and private diagnostic chains are digitizing slides and could use morphology-based triage for blood cancers.
6. Other information
Co-founders: Christian Ruiz (CEO), Nicole H. Romano (CTO), Stefan Habringer (CMO). Seed round of EUR 2.8 million announced 6 May 2026, co-led by Lotus One Investment, VP Venture Partners and MEDIN Fund, with N&V Capital and QAI Ventures. Founding year not stated on fetched pages.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































